Last updated: September 4, 2026
Aliskiren hemifumarate/amlodipine besylate is the fixed-dose antihypertensive marketed in the United States as Tekamlo by Novartis. Its commercial trajectory has been constrained by three factors: generic availability of amlodipine, declining clinical confidence in aliskiren after the ALTITUDE trial, and broad generic competition against aliskiren-containing products. The combination has no meaningful biosimilar risk because it is a small-molecule drug, but it faces high generic substitution risk and limited remaining exclusivity value.
What is aliskiren hemifumarate and amlodipine besylate?
Aliskiren hemifumarate/amlodipine besylate combines two antihypertensive mechanisms:
| Component |
Drug class |
Primary mechanism |
Generic status |
| Aliskiren hemifumarate |
Direct renin inhibitor |
Reduces renin activity and downstream angiotensin formation |
Generic available |
| Amlodipine besylate |
Dihydropyridine calcium-channel blocker |
Relaxes arterial smooth muscle and lowers peripheral resistance |
Generic widely available |
The U.S. product, Tekamlo, was approved by the FDA on November 23, 2009, under NDA 022275. It was approved for the treatment of hypertension in patients who require more than one drug to control blood pressure. Available strengths included aliskiren/amlodipine combinations ranging from 150/5 mg to 300/10 mg, depending on the marketed presentation and labeling history. [1]
The combination was designed to compete with established antihypertensive combinations involving an angiotensin receptor blocker, an angiotensin-converting enzyme inhibitor, or a calcium-channel blocker. Its commercial differentiation depended on aliskiren’s direct renin inhibition rather than on a novel delivery system or proprietary formulation.
When did Tekamlo lose exclusivity?
Tekamlo’s effective market exclusivity ended after the expiration or loss of practical value of the relevant aliskiren and combination-product protections. Amlodipine itself had already lost U.S. patent exclusivity before Tekamlo launched.
Key exclusivity milestones
| Milestone |
Approximate date |
Commercial effect |
| Amlodipine core patent protection ended |
2007-2009 period |
Generic amlodipine became broadly available |
| Tekamlo FDA approval |
November 23, 2009 |
Launch of fixed-dose combination |
| Aliskiren safety concerns intensified after ALTITUDE |
2012 |
Reduced physician adoption and regulatory confidence |
| U.S. aliskiren composition protection reached its principal expiry period |
2022 |
Generic aliskiren competition became commercially viable |
| Current commercial position |
Post-exclusivity |
Low-value branded combination with generic substitution pressure |
The aliskiren patent estate provided the principal exclusivity value. Amlodipine contributed clinical utility but little residual patent strength because generic amlodipine was already established.
Tekamlo may have qualified for statutory pediatric extensions or patent-term adjustments affecting individual patents, but those provisions did not create a durable commercial franchise. The practical exclusivity period ended well before the product could establish a large market share.
What patents protect aliskiren and Tekamlo?
The patent estate centered on aliskiren’s active pharmaceutical ingredient, pharmaceutical compositions, salts, and selected therapeutic uses. Amlodipine protection was largely exhausted by the time the fixed-dose combination reached the market.
Principal patent categories
| Patent category |
Protected subject matter |
Strategic value |
| Aliskiren compound patents |
Direct renin inhibitor chemical structure |
Historically central |
| Salt and solid-state patents |
Aliskiren hemifumarate and related forms |
Moderate, depending on claim scope |
| Pharmaceutical composition patents |
Tablets containing aliskiren, alone or with other agents |
Potentially relevant to combination products |
| Combination patents |
Aliskiren with calcium-channel blockers or other antihypertensives |
Narrower and more vulnerable to design-around |
| Method-of-use patents |
Treatment of hypertension and cardiovascular risk |
Limited after broad generic entry |
| Amlodipine patents |
Compound and formulation claims |
Mostly expired before Tekamlo’s commercial maturity |
Novartis and affiliated entities were the principal originator patent holders associated with aliskiren and Tekamlo. Public FDA records identify Tekamlo as an approved combination product, but the commercial value of any remaining patent claims is limited by the age of the product, broad generic availability of its individual ingredients, and weak physician demand for direct renin inhibition. [1, 2]
What is the Orange Book status of Tekamlo?
Tekamlo was listed in FDA regulatory records as a prescription combination product. The relevant Orange Book analysis depends on the specific National Drug Code, listing status, and whether the product is classified as discontinued rather than withdrawn for safety or effectiveness reasons.
The key regulatory distinction is that commercial discontinuation does not automatically mean FDA withdrawal. A product can remain in FDA databases while no longer being actively marketed. The practical market question is whether the brand has current supply, active promotional support, and a reimbursed commercial channel.
No biosimilar pathway applies. Aliskiren and amlodipine are chemically synthesized small molecules, so competitive entry occurs through abbreviated new drug applications, not through the biologics license application and biosimilar pathways.
What FDA safety issues affected aliskiren demand?
The main commercial setback came from the ALTITUDE trial, which evaluated aliskiren in high-risk patients with type 2 diabetes and renal impairment or cardiovascular disease who were also receiving an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.
The trial was stopped early after the aliskiren arm showed increased risks involving renal impairment, hyperkalemia, hypotension, and nonfatal stroke without demonstrated clinical benefit. The FDA subsequently warned against using aliskiren with ACE inhibitors or ARBs in patients with diabetes and against such combinations in patients with moderate to severe renal impairment. [3]
The safety issue did not eliminate all approved use of aliskiren. It narrowed the appropriate patient population and weakened the rationale for choosing aliskiren over established generic alternatives. That change had a direct effect on Tekamlo because the product’s value depended on aliskiren as the differentiated component.
How did the market for Tekamlo develop?
Tekamlo entered a mature hypertension market dominated by inexpensive generic drugs. Its commercial proposition was a single tablet combining a direct renin inhibitor with amlodipine. That proposition faced several barriers:
- Amlodipine was already available at low cost as a single generic drug.
- Physicians had extensive experience with amlodipine combined with ACE inhibitors or ARBs.
- Aliskiren lacked a clear outcome advantage over established renin-angiotensin-system therapies.
- The ALTITUDE findings reduced use in important high-risk populations.
- Payers had limited incentive to reimburse a branded combination when the ingredients were available separately.
The product therefore occupied a narrow treatment segment. It was most commercially relevant for patients requiring dual therapy who had a reason to avoid an ACE inhibitor or ARB, but that segment was insufficient to support durable brand growth.
What was the financial trajectory of aliskiren and Tekamlo?
Novartis did not consistently report Tekamlo as a separately material revenue line in public annual reports. Product-level revenue disclosure was generally grouped within broader pharmaceutical portfolio reporting. As a result, Tekamlo’s standalone sales cannot be reconstructed reliably from consolidated filings.
The financial trajectory can be divided into four stages:
| Period |
Financial condition |
Main driver |
| 2009-2011 |
Initial commercialization |
Launch of Tekamlo and broader aliskiren franchise |
| 2012-2014 |
Declining momentum |
ALTITUDE results, regulatory restrictions, reduced prescribing |
| 2015-2021 |
Mature low-growth or declining brand |
Generic amlodipine, limited differentiation, portfolio reprioritization |
| 2022 onward |
Generic-era economics |
Loss of aliskiren exclusivity and low branded pricing power |
Aliskiren’s broader franchise had more commercial importance than Tekamlo alone because it included Tekturna, Rasilez, and other combinations. Even at the franchise level, sales growth was limited by clinical positioning and competition from generic renin-angiotensin-system therapies.
The product’s revenue exposure was therefore low relative to Novartis’s major oncology, immunology, and cardiovascular brands. The fixed-dose combination did not develop into a strategic growth asset, and the economics were more consistent with late-life portfolio maintenance than with active lifecycle expansion.
Which companies are challenging Tekamlo?
The principal competitive risk comes from generic manufacturers rather than from a high-profile branded challenger. Potential competitors include manufacturers of:
- Generic amlodipine
- Generic aliskiren
- Separate-tablet aliskiren and amlodipine regimens
- Other two-drug antihypertensive combinations
- Fixed-dose combinations containing amlodipine with an ACE inhibitor or ARB
A generic company does not need to reproduce the commercial strength of the Tekamlo brand to compete. It can offer aliskiren and amlodipine separately, substitute generic amlodipine into treatment, or seek approval for a therapeutically equivalent fixed-dose product if the relevant regulatory and patent requirements are satisfied.
Were there Paragraph IV challenges to Tekamlo?
Paragraph IV litigation risk was more significant for aliskiren’s core patents and related products than for Tekamlo as a standalone commercial asset. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. The first accepted ANDA containing a Paragraph IV certification can trigger a 30-month stay under the Hatch-Waxman framework if the brand sponsor files a timely infringement action. [4]
The principal litigation exposure involved:
- Aliskiren active-ingredient patents
- Salt and formulation patents
- Combination-product patents
- Patents covering related aliskiren products such as Tekturna and Valturna
The economic impact of any Paragraph IV challenge was limited by the declining demand for aliskiren. A patent dispute can preserve nominal exclusivity while failing to preserve substantial revenue if prescribers and payers have already shifted away from the product.
How strong is the patent estate for aliskiren/amlodipine?
The estate is weak from a current commercial perspective.
Strengths
- Aliskiren’s compound patents provided meaningful early exclusivity.
- Salt and formulation claims could delay or complicate generic development.
- Combination claims could create additional regulatory or litigation barriers.
Weaknesses
- Amlodipine was already generic at launch.
- The most important aliskiren exclusivity period has expired.
- Combination claims are generally narrower than compound claims.
- Separate generic use of the two ingredients limits the value of a fixed-dose product patent.
- Safety concerns reduced the commercial value of surviving claims.
The estate has historical importance but little current licensing or litigation value. A generic manufacturer would likely evaluate the product based on formulation economics, regulatory feasibility, and market access rather than on the existence of a durable originator moat.
What manufacturing and geographic barriers remain?
Manufacturing barriers are moderate rather than high. Aliskiren is more complex to synthesize than amlodipine and may require greater control of stereochemistry, impurities, solid-state properties, and salt formation. Amlodipine is a mature generic ingredient with established manufacturing capacity.
The most relevant barriers are:
- Aliskiren active-ingredient cost
- Control of polymorphic or salt forms
- Bioequivalence requirements for the fixed-dose product
- Limited commercial demand
- Country-specific patent and regulatory status
- Low reimbursement for a niche combination
Geographic protection is uneven. U.S. patent expiry does not establish the same date in Europe, Japan, Canada, or emerging markets. Originator rights, supplementary protection certificates, data exclusivity, and local regulatory filings must be assessed separately. The commercial importance of those differences is reduced where physicians can prescribe separate generic ingredients.
How does Tekamlo compare with competing antihypertensive combinations?
| Product type |
Patent position |
Clinical adoption |
Commercial outlook |
| Aliskiren/amlodipine |
Mature or expired protection |
Limited |
Weak |
| Amlodipine/benazepril |
Generic competition |
Established |
Low-cost, durable demand |
| Amlodipine/valsartan |
Generic competition |
Established |
Broad substitution |
| Amlodipine/losartan |
Generic competition |
Established |
Strong payer acceptance |
| Amlodipine alone |
Fully generic |
Very high |
Commodity market |
| Aliskiren alone |
Generic competition |
Limited |
Narrow niche |
Tekamlo is disadvantaged because its novel component, aliskiren, does not have the same guideline position or utilization base as ACE inhibitors and ARBs. Amlodipine remains commercially relevant, but that value accrues primarily to generic manufacturers rather than to the fixed-dose aliskiren combination.
What generic launch scenarios exist?
The most likely market scenarios are:
- Generic substitution through separate aliskiren and amlodipine prescriptions.
- Limited fixed-dose generic entry if manufacturing and regulatory costs are justified.
- Continued brand erosion without a large launch because total market demand is small.
- Withdrawal of active branded promotion and migration to low-cost generic channels.
A successful generic launch would likely produce rapid price compression. The reference product would retain limited value among patients stabilized on the branded tablet, but formulary pressure would favor generic alternatives.
Key Takeaways
- Tekamlo is the U.S. fixed-dose combination of aliskiren hemifumarate and amlodipine besylate, approved in 2009.
- Amlodipine was already generic when Tekamlo launched, leaving aliskiren as the primary source of differentiation.
- The ALTITUDE trial materially weakened aliskiren’s clinical and commercial position.
- Aliskiren’s principal U.S. exclusivity period reached its end in the early 2020s.
- Tekamlo has no biosimilar risk, but it has substantial generic substitution risk.
- Novartis did not report Tekamlo as a consistently separate material revenue line.
- The current patent estate has limited practical value because of expired core rights, generic ingredients, narrow combination claims, and weak demand.
- The most probable commercial outcome is low-value generic competition rather than a major branded recovery.
FAQs
Is Tekamlo still marketed in the United States?
Tekamlo has had limited commercial relevance in the United States, and FDA database presence does not necessarily indicate active commercial distribution. Its market position is substantially weaker than during the initial launch period.
Can patients take generic aliskiren and generic amlodipine separately?
Yes. Separate administration can provide the same active ingredients, although dose selection, adherence, labeling, and prescriber instructions differ from use of a fixed-dose tablet.
Does aliskiren have stronger patents than amlodipine?
Historically, yes. Aliskiren’s compound and related patents supplied the main exclusivity value. Amlodipine patents had largely expired before Tekamlo became commercially established.
Is aliskiren recommended with an ACE inhibitor or ARB?
The FDA restricts use of aliskiren with ACE inhibitors or ARBs in patients with diabetes and warns against such combinations in patients with moderate to severe renal impairment because of renal, potassium, and blood-pressure risks. [3]
Could a generic company obtain approval for a fixed-dose aliskiren/amlodipine product?
Yes, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, labeling, manufacturing quality, and resolution of any applicable patent or exclusivity issues. The limited market size may be a greater barrier than the regulatory pathway.
References
-
U.S. Food and Drug Administration. (2009). Tekamlo: Aliskiren hemifumarate and amlodipine besylate prescribing information. FDA Drugs@FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2012). FDA drug safety communication: New warning and contraindication for blood pressure medicines containing aliskiren. FDA.
-
U.S. Food and Drug Administration. (2017). Abbreviated new drug application approvals and patent certifications under the Hatch-Waxman Act. FDA.
-
Novartis AG. (2010-2023). Annual reports and financial statements. Basel, Switzerland: Novartis.
